Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-5204 (Stillen 2X) in GERD
NCT03998969Phase 3Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Pantoprazole + DA-5204 with Pantoprazole + Placebo (2 arms). Primary endpoints: Endoscopically effective improvement at 4 weeks and Endoscopically complete improvement at 4 weeks. Started Jun 2016; status: completed.
02
Drugs
Stillen
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03998969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998969.